MARKHAM, ON, Nov. 7 /PRNewswire-FirstCall/ - AlphaRx is pleased to announce pre-clinical data on Vansolin(TM), a Vancomycin compound encapsulated in the company's Nano Drug Delivery Platform intended for the treatment of nosocomial pneumonia.
In the recent clinical trial, mice treated with Vansolin(TM) in a Murine Model of Pneumonia showed better efficacy than Vancomycin, achieving 100% survival rate vs. 30% in the Vancomycin treatment group. With these results, Vansolin(TM) is now on track to enter into human trials in 2008.
These results support The Company's belief that encapsulating Vancomycin into AlphaRx's nano-particle formulation may increase its efficacy. According to published research papers, in vitro uptake of Vancomycin nanoparticles by white blood cells is 20 times greater than free drug. The Company anticipates that in vivo, after IV infusion, white blood cells will readily absorb Vansolin nanoparticles and transport them to the site of inflammation and infection, thereby increasing the local concentration of Vancomycin and ultimately increasing its bactericidal effect.
What's more, in the Murine Model of Pneumonia, Vancomycin encapsulated in the company's Nano Drug Delivery platform administrated by injection of 1 mg/kg, is more effective than injecting 10 mg/kg, in a conventional formulation in terms of mortality. The 90% reduction in dosage is significant, in that it may reduce potential toxicity effects of Vancomycin and may reduce treatment days from 10 days to 3 days.
Currently, the Company has four nano products in the development pipeline with an estimated annual market sales potential of over US$6.0 billion dollars.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
CONTACT: Nucap Investor Relations, Web: http://www.thenucap.com, E-mail:
aorlando@thenucap.com; John Young, Managing Partner, 629 Fifth Avenue,
Suite 300, Pelham, NY, 10803, (914) 924-7437, jyoung@thenucap.com,
www.thenucap.com
